A success story: IDH inhibitors for AML
Is venetoclax a game changer in AML therapy?
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential
An exciting development: FLT3 inhibitors as a combination therapy?
Overcoming venetoclax resistance in AML with MCL1 inhibition